Examining valganciclovir prophylaxis duration among high-risk donor seropositive/recipient seronegative heart transplant recipients in a larger cohort

Transpl Infect Dis. 2021 Aug;23(4):e13581. doi: 10.1111/tid.13581. Epub 2021 Feb 18.

¹ Division of Allergy and Infectious Diseases, Department of Internal Medicine, University of Washington, Seattle, WA, USA.
² Division of Infectious Diseases, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
³ University of Washington, Seattle, WA, USA.
⁴ Department of Pharmacology, University of Washington, Seattle, WA, USA.
⁵ Department of Internal Medicine, Division of Cardiology, University of Washington, Seattle, WA, USA.

No abstract available

Keywords: cytomegalovirus; heart transplant; valganciclovir.

Publication types